The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials

Shen-Peng Chang\textsuperscript{1}
Hong-Zin Lee\textsuperscript{2}
Chih-Cheng Lai\textsuperscript{3}
Hung-Jen Tang\textsuperscript{4}

\textsuperscript{1}Department of Pharmacy, Chi Mei Medical Center, Liouying, Taiwan; \textsuperscript{2}School of Pharmacy, China Medical University, Taichung, Taiwan; \textsuperscript{3}Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Taiwan; \textsuperscript{4}Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan

\textbf{Objectives:} This meta-analysis aims to assess the clinical efficacy and safety of nemonoxacin in comparison with levofloxacin in treating community-acquired pneumonia (CAP).

\textbf{Materials and methods:} The Pubmed, Embase, ClinicalTrials.gov, and the Cochrane databases were searched up to September 2018. Only randomized controlled trials (RCTs) evaluating nemonoxacin and levofloxacin in the treatment of CAP were included. The primary outcome was the clinical cure rate, and the secondary outcomes included the microbiologic response rate and the risk of adverse events.

\textbf{Results:} Three RCTs were included. Overall, nemonoxacin and levofloxacin had similar clinical cure rates in the treatment of CAP (OR = 1.05, 95\% CI = 0.67–1.64, \(p = 0\%\)). Nemonoxacin also had a microbiologic response rate similar to levofloxacin (OR = 0.89, 95\% CI = 0.44–1.81, \(p = 0\%\)). No significant differences were found in treatment-emergent adverse events between the two drugs (OR = 1.08, 95\% CI = 0.81–1.43, \(p = 0\%\)). In subgroup analysis, the similarities in the clinical cure rate, microbiologic response rate, and risk of adverse events of these two drugs remained unchanged with the dose of nemonoxacin (500 or 750 mg) and individual pathogens.

\textbf{Conclusion:} The clinical and microbiologic efficacy of nemonoxacin is comparable to that of levofloxacin in the treatment of CAP, and this agent is as well tolerated as levofloxacin.

\textbf{Keywords:} nemonoxacin, levofloxacin, community-acquired pneumonia

\section*{Introduction}
Community-acquired pneumonia (CAP) is a common type of infection that can be caused by a variety of microorganisms, including typical pathogens such as \textit{Streptococcus pneumoniae} and \textit{Haemophilus influenzae} and atypical pathogens such as \textit{Mycoplasma pneumoniae}, \textit{Chlamydia pneumoniae}, and \textit{Legionella} species.\textsuperscript{1,2} In the face of the high morbidity and mortality of this disease, an appropriate antibiotic is the key to treatment.\textsuperscript{3} Respiratory quinolones, including levofloxacin and moxifloxacin, have good in vitro and in vivo activity against typical and atypical CAP pathogens and are recommended for treatment.\textsuperscript{3}

Nemonoxacin is a recently developed novel quinolone. In contrast to other quinolones, nemonoxacin is a nonfluorinated C-8 methoxy quinolone which targets DNA gyrase and topoisomerase IV. Many in vitro studies have demonstrated its great antibacterial activity.\textsuperscript{4–8} Nemonoxacin also displays good in vitro activity against some antibiotic-resistant pathogens such as methicillin-resistant \textit{Staphylococcus}
aureus, penicillin-resistant Streptococcus pneumoniae, and ertapenem-non-susceptible Enterobacteriaceae. All of these findings suggest that nemonoxacin may play a role in the treatment of CAP. Nemonoxacin exhibits poor activity against Mycobacterium tuberculosis (tuberculosis [TB]), including both multidrug-resistant (MDR) TB and non-MDR-TB. Thus, unlike levofloxacin and moxifloxacin, which are active against TB, nemonoxacin may bring an additional benefit in the clinical setting of CAP as its use would not mask or delay the diagnosis of TB.

Recently, several clinical trials have investigated the clinical efficacy and safety of nemonoxacin in the treatment of CAP. But there has been no systematic review or meta-analysis comparing the efficacy and safety of nemonoxacin and other quinolones in treating CAP. Therefore, we performed a comprehensive meta-analysis to provide better evidence on the efficacy and safety of nemonoxacin in treating CAP.

Materials and methods

Study search and selection

All clinical studies were identified by a systematic review of the literature in the PubMed, Embase, ClinicalTrials.gov, and Cochrane databases until September 2018 using the following search terms – nemonoxacin, TG-873870, and Taigexyn. Only the clinical studies that compared the clinical efficacy and adverse effects of nemonoxacin and other comparators were included. Two reviewers (Chang and Lee) searched and examined publications independently to avoid bias. When they disagreed, the third author (Lai) resolved the issue. The following data were extracted from every included study: year of publication, study design, sites and duration, antibiotic regimens of nemonoxacin and comparators, outcomes, and adverse events.

Definitions and outcomes

The primary outcome was overall clinical cure with resolution of clinical signs and symptoms of pneumonia, or recovery to the pretreatment state as the test of cure (TOC). Secondary outcomes included the microbiologic response rate and adverse events. A microbiologic response was defined as eradication (the baseline pathogen was absent) and presumed eradication (if an adequate source specimen was not available to culture, but the patient was assessed as clinically cured) at the TOC visit. Treatment-emergent adverse events were recorded, irrespective of causality. Finally, we used the results of intent-to-treat analysis for this meta-analysis.

Data analysis

This study used the Cochrane Risk of Bias Assessment tool to assess the quality of enrolled randomized controlled trials (RCTs) and the risk of bias. The software Review Manager, version 5.3 was used to conduct the statistical analyses. The degree of heterogeneity was evaluated with the Q statistic generated from the chi-squared test. The proportion of statistical heterogeneity was assessed by the I² measure. Heterogeneity was considered significant when the P-value was <0.10 or the I² was >50%. The random-effects model was used when the data were significantly heterogeneous, and the fixed-effect model was used when the data were homogenous. Pooled ORs and 95% CIs were calculated for outcome analyses.

Results

Study selection and characteristics

The search program yielded 189 references, including 47 from PubMed, 111 from Embase, 19 from the Cochrane database, and 12 from ClinicalTrials.gov. Finally, three studies fulfilling the inclusion criteria were included in this meta-analysis (Figure 1). All studies were randomized, double-blind, multicenter studies that were designed to compare the clinical efficacy and safety of nemonoxacin with levofloxacin for adult patients with CAP (Table 1). Two studies assigned CAP patients to one of three treatment groups (nemonoxacin 750 mg, nemonoxacin 500 mg, and levofloxacin 500 mg) in a 1:1:1 ratio. Another study assigned patients in a 2:1 ratio to receive nemonoxacin 500 mg or levofloxacin 500 mg for 7–10 days. Most of the domains were classified as having a low risk of bias, except for incomplete outcome data in one study (Figures 2 and 3).

Clinical efficacy

Overall, nemonoxacin had a clinical cure rate similar to levofloxacin in the treatment of CAP (OR =1.05, 95% CI =0.67–1.64, P=0%; Figure 4). In addition, all the enrolled studies found no significant differences in the clinical cure rates of patients treated with nemonoxacin 500 mg and levofloxacin 500 mg (OR =1.01, 95% CI =0.62–1.65, F=0%). Only two included studies compared the clinical cure rates of nemonoxacin 750 mg and levofloxacin 500 mg and no significant difference was found (OR =1.09, 95% CI =0.58–2.05, F=0%). Nemonoxacin and levofloxacin exhibited similar clinical responses against Streptococcus pneumoniae (OR =1.20, 95% CI =0.21–6.75, F=0%), Haemophilus spp. (OR =0.77, 95% CI =0.16–3.63, F=0%), Staphylococcus aureus
In subgroup analysis, there were no significant differences in the clinical cure rate (OR = 0.99, 95% CI = 0.33–2.90, $P=0\%$).

**Adverse events**

No significant differences were found for treatment-emergent adverse events in overall and subgroup comparisons (nemonoxacin at 500 or 750 mg vs levofloxacin 500 mg: OR = 1.08, 95% CI = 0.81–1.43, $P=0\%$; Figure 6; nemonoxacin at 500 mg vs levofloxacin 500 mg: OR = 0.95, 95% CI = 0.71–1.28, $P=0\%$; nemonoxacin at 750 mg vs levofloxacin 500 mg: OR = 1.46, 95% CI = 0.92–2.31, $P=0\%$).

**Comparison between nemonoxacin dosages of 750 and 500 mg**

In subgroup analysis, there were no significant differences in the clinical cure rate (OR = 0.99, 95% CI = 0.33–2.99, $P=0\%$).

### Table 1 Characteristics of included studies

<table>
<thead>
<tr>
<th>Study, published year</th>
<th>Study design</th>
<th>Study site</th>
<th>Study period</th>
<th>Study population</th>
<th>No of patients</th>
<th>Dose regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>van Rensburg et al, 2010</td>
<td>Multicenter, randomized, double-blind, non-inferiority trial</td>
<td>South Africa, Taiwan</td>
<td>2006–2007</td>
<td>Mild to moderate CAP</td>
<td>89 (500 mg) 86 (750 mg)</td>
<td>90</td>
</tr>
<tr>
<td>Liu et al, 2017</td>
<td>Multicenter, randomized, double-blind, non-inferiority trial</td>
<td>China</td>
<td>2009–2010</td>
<td>Chinese patients with mild to moderate CAP</td>
<td>65 (500 mg) 65 (750 mg)</td>
<td>62</td>
</tr>
<tr>
<td>Yuan et al, 2017</td>
<td>Multicenter, randomized, double-blind, non-inferiority trial</td>
<td>China, Taiwan</td>
<td>2011–2012</td>
<td>Chinese patients with CAP</td>
<td>357 (500 mg)</td>
<td>175</td>
</tr>
</tbody>
</table>

Abbreviation: CAP, community-acquired pneumonia

(OR = 2.29, 95% CI = 0.12–41.98, $P=0\%$), and atypical pathogens (OR = 0.80, 95% CI = 0.17–1.92, $P=0\%$).

**Microbiologic response**

Nemonoxacin had a microbiologic response rate similar to levofloxacin in the treatment of CAP (OR = 0.89, 95% CI = 0.44–1.81, $P=0\%$; Figure 5). Three enrolled studies$^{16–18}$ compared the microbiologic response of nemonoxacin 500 mg with levofloxacin 500 mg and found no significant differences (OR = 0.83, 95% CI = 0.39–1.77, $P=0\%$). Two included studies$^{16,17}$ compared the microbiologic response between nemonoxacin 750 mg and levofloxacin 500 mg and found no significant difference (OR = 0.98, 95% CI = 0.33–2.90, $P=0\%$).
$I^2=57\%$) and microbiologic response rate (OR =1.38, 95% CI =0.49–3.95, $I^2=0\%$) between different doses of nemonoxacin (750 and 500 mg). However, the 750 mg dosage of nemonoxacin had a higher risk of treatment-emergent adverse events than the 500 mg dose (OR =1.63, 95% CI =1.03–2.58, $I^2=0\%$).

Discussion

Several findings from this meta-analysis based on three RCTs showed that nemonoxacin has a clinical efficacy similar to levofloxacin in the treatment of adult patients with CAP. First, the clinical cure rate of nemonoxacin in treating CAP was as good as levofloxacin. Second, the microbiologic response rate of nemonoxacin was similar to levofloxacin. Third, subgroup analysis of different pathogens, including *Streptococcus pneumoniae*, *Haemophilus* spp., *Staphylococcus aureus*, and atypical pathogens, showed no significant differences in the clinical efficacy of these two drugs in the treatment of CAP. Finally, both the 500 and 750 mg dosages of nemonoxacin had clinical and microbiologic responses similar to levofloxacin. All of these findings are supported by in vitro and in vivo studies, showing that the activity of nemonoxacin is comparable to levofloxacin. Therefore, based on the findings of these analyses, it is suggested that nemonoxacin can play an important role similar to levofloxacin in the treatment of CAP.

The risk of adverse events is another important concern in the treatment of CAP with this novel antimicrobial agent. Most of the treatment-emergent adverse events among nemonoxacin users were mild, and nausea, vomiting, leukopenia, and abnormal liver function were the most common adverse events. In this analysis, the pooled risks of treatment-emergent adverse effects were similar between nemonoxacin and levofloxacin. Even with a higher dose of nemonoxacin (750 mg), there was no significance difference in the safety between these two drugs. All of these findings suggest that nemonoxacin is as safe as levofloxacin in the treatment of CAP.

We also found that there were no significant differences in the clinical cure and microbiologic response rates between the
nemonoxacin dosages of 500 and 750 mg. However, the 750 mg dosage had a significantly higher risk of adverse effects than the 500 mg dosage. Nemonoxacin 500 mg regimen may be adequate for the treatment of CAP.

This meta-analysis has one major strength. Only RCTs were included, so the risk of bias is minimized, and the level of evidence is strong. However, this meta-analysis also has several limitations. First, most cases of CAP in this meta-analysis were mild to moderate, and all patients in these three RCTs received only oral nemonoxacin. Therefore, further study is needed to investigate the use of nemonoxacin in severe CAP. Second, we did not evaluate the association between in vitro activity and the in vivo response of different organisms, especially for antibiotic-resistant pathogens. Finally, the numbers of studies and patients were limited in this meta-analysis, and therefore, the formal test for heterogeneity may be underestimating the degree of heterogeneity. In addition, only Asians and Africans were enrolled in these three RCTs. Therefore, these findings may not be generalized to other countries. Further large-scale study is warranted.

In conclusion, based on the findings of this meta-analysis of three RCTs, the clinical and microbiologic efficacy of nemonoxacin is as good as levofloxacin in the treatment of CAP, and this antibiotic is as well tolerated as levofloxacin. Thus, nemonoxacin can be recommended as an appropriate antibiotic therapy for CAP.
Disclosure

The authors report no conflicts of interest in this work.

References